ERBB2 and neoplasm: In these CFPAC-1 mice we observed no difference in HER2.CART infiltration or expansion at the tumor site or circulating IFNγ levels in the blood of mice treated with either HER2.CART alone or combination therapy (Fig. 2b, c).